• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Bifeprunox     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : umbel-rc:DrugProduct, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatAtypicalAntipsychoticsyago:WikicatMolecularFormulasyago:Abstraction100002137yago:Agent114778436yago:CausalAgent100007347yago:Communication100033020yago:Drug103247620yago:DrugOfAbuse103248958yago:Formula106816935yago:MajorTranquilizer103713736yago:Matter100020827yago:Medicine103740161yago:Message106598915yago:MolecularFormula106817173yago:PhysicalEntity100001930yago:Piperazine103946814yago:PsychotropicAgent104017429drugyago:Sedative-hypnotic104166841yago:Sedative104166553yago:Statement106722453yago:Substance100020090yago:Tranquilizer104470232yago:Vermifuge104528630yago:WikicatPiperazinesumbel-rc:DrugProduct New Facet based on Instances of this Class

Bifeprunox (INN) (code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D2 receptor agonism with serotonin receptor agonism. It was under development for the treatment of schizophrenia but has since been abandoned. In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects.